INTRODUCTION

Lymphopenia is commonly observed in COVID-19 patients although the lymphocyte count is not always below 0.8 × 10⁹/L in all the patients. It is suggested that lymphopenia serves as a useful predictor for prognosis in the patients. It is also hypothesized that lymphopenia is related to glucocorticoids and apoptosis. However, the ordering between lymphopenia and apoptosis appears different between SARS and COVID-19 patients, i.e., lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients. This paper attempts to figure out this contradiction through three players, lymphopenia, glucocorticoids, and apoptosis. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, this paper raises several questions, which need to be answered in order to better understand the whole course of COVID-19.

KEYWORDS
COVID-19, lymphopenia, glucocorticoids, apoptosis, SARS-CoV, SARS-CoV-2
Now lymphopenia appears again in the current COVID-19 pandemic. As a matter of fact, lymphopenia is not exclusively in SARS and COVID-19 patients (right-hand part in Figure 1), but can be found in many medical conditions, e.g., sepsis, severe trauma, extensive burns, and major surgery. Typically lymphopenia is followed by immunosuppression (left-hand part in Figure 1). Lymphopenia in SARS patients is attributed to the endogenous glucocorticoids and apoptosis (central vertical part in Figure 1). (a) SARS-CoV initially triggers a stress response to stimulate the hypothalamic-pituitary-adrenal axis (the black arrow at the top right-hand part in Figure 1) to generate an excessive amount of endogenous glucocorticoids, which cause lymphocytes to move out from the peripheral circulation and apoptosis of lymphocytes (central vertical part). Two signaling pathways induce apoptosis: mitochondrial pathway and death receptor pathway (left-hand lower part). The activation of p53 can inhibit the replication of SARS-CoV and SARS-CoV-2, and also induce apoptosis in lymphocytes (right-hand lower part). Consequently, lymphocyte apoptosis brings about the damage of the immune system and immune suppression (bottom part). ACE2, the angiotensin I-converting enzyme 2; TACE, the TNF-α-converting enzyme; TMPRSS2, the cellular serine protease.

FIGURE 1  Mechanism for lymphopenia in SARS and COVID-19 patients. Decreased amount of lymphocytes in circulation causes lymphopenia (central violet rectangle). This symptom can be found in SARS and COVID-19 patients as well as in the patients with sepsis, severe trauma, extensive burns, major surgery (top part). These circumstances trigger a stress response to stimulate the hypothalamic-pituitary-adrenal axis. Both an excessive amount of endogenous glucocorticoids (green arrows) and exogenous glucocorticoids (orange arrows) cause lymphocytes to move out from the peripheral circulation and apoptosis of lymphocytes (central vertical part). Two signaling pathways induce apoptosis: mitochondrial pathway and death receptor pathway (left-hand lower part). The activation of p53 can inhibit the replication of SARS-CoV and SARS-CoV-2, and also induce apoptosis in lymphocytes (right-hand lower part). Consequently, lymphocyte apoptosis brings about the damage of the immune system and immune suppression (bottom part). ACE2, the angiotensin I-converting enzyme 2; TACE, the TNF-α-converting enzyme; TMPRSS2, the cellular serine protease.
although it is not clear whether a corticotropin test was performed.

Lymphopenia is also attributed to the exogenous glucocorticoids, which were given to SARS patients with different dosages, eg, methylprednisolone ≥ 500 mg/day,24 prednisolone 0.5–1 mg/kg/day, hydrocortisone (100 mg every 8 h), methylprednisolone 500 mg/day up to 3000 mg/day.25 Basically, a high dose of glucocorticoids activates the genes, which encode anti-inflammatory proteins (right-hand middle part in Figure 1), whereas a low dose of glucocorticoids suppresses inflammatory genes (left-hand middle part in Figure 1).26

Corticosteroid mainly leads T lymphocytes to leave from the peripheral circulation and then enter into the bone marrow (left-hand middle part in Figure 1).27 However, lymphocytic infiltration was sparse in lungs, and lymphocytes decreased in spleen and lymph nodes in SARS patients (right-hand middle part in Figure 1).22 Furthermore, T lymphocytes distributed mainly at the periphery of the germinal centers of the splenic white pulp, lymph nodes, and peripheral blood in SARS patients (right-hand middle part in Figure 1).22 These results imply that other types of lymphocytes might not leave from the peripheral circulation except for T lymphocytes.

Thus, it is easy to see that lymphopenia in SARS patients occurs first and then the apoptosis of lymphocytes follows.29 For a different reason, the KEGG pathway analysis in transcriptomic data suggests that lymphocytes probably undergo apoptosis through the p53 signaling pathway,30 which in turn leads to lymphopenia in COVID-19 patients.3,30 These findings suggest that the apoptosis of lymphocytes occurs before lymphopenia (lower middle part in Figure 1), ie, the ordering between lymphopenia and lymphocyte apoptosis appears different for SARS patients and COVID-19 patients.

In summary, this section raises two questions. (a) Does a COVID-19 patient with adrenal insufficiency have a better outcome since the amount of glucocorticoids inside circulation may not be sufficient to lead to lymphopenia? (b) Which event is the first between lymphopenia and lymphocyte apoptosis (up-down arrow in lower middle part in Figure 1)?

2 | CAN SARS-COV AND SARS-COV-2 INFECT LYMPHOCYTES?

To infect a host cell, both SARS-CoV and SARS-CoV-2 at first need to recognize the angiotensin I-converting enzyme 2 (ACE2) receptor on the surface of the host cell by its spike protein.31–34 Meanwhile, it is unknown whether the spike protein from SARS-CoV-2, like the spike protein from SARS-CoV,35 can down-regulate ACE2 expression. It turns out that several coronaviruses including SARS-CoV-2,32 SARS-CoV,35 and HNL63-CoV36,37 enter into the host cell in such a way. In contrast, HCoV-229E uses CD13 as its entering the cellular receptor.38 Together with ACE2, TNF-α-converting enzyme (TACE) is also positively involved in SARS-CoV entry into host cells.39

Therefore, ACE2-positive cells are the prerequisite for cells to be infected by SARS-CoV35,40 and SARS-CoV-2.32 The ACE2 receptor widely exists on the surface of human cells, especially in the alveolar type II cells and capillary endothelium in lung,22,41,42 the upper respiratory tract,42 and other human tissues such as heart, liver, kidney, and digestive organs.42,43 Nevertheless, SARS-CoV mainly infects pneumocytes and macrophages in the lung,44 subsequently ACE2 plays a particular role in lung injury.39,45 Currently, these findings and implications are applicable to SARS-CoV-2 although more studies are in need to expand our knowledge on SARS-CoV-2.

On the other hand, the cells related immune system, ie, bone marrow, lymph nodes, thymus, spleen, T and B lymphocytes, and macrophages, are consistently negative for ACE2 (two yellow rectangles in Figure 1).42 In reality, SARS-CoV is unlikely to cause massive infection in lymphocytes because SARS-CoV was found in lymphocytes only in 6 of 22 early stage patients, of which 51.5% of lymphocytes were SARS-CoV positive.22 This low infection rate in lymphocytes should partly result from the absence of ACE2 in lymphocytes. To take a step further, if lymphocytes lack ACE2, then TACE, which works with ACE2 together,39 would not exist in lymphocytes.

The innate immune system has three classes of cytoplasmic pattern recognition receptors to respond to virus: toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs). They recognize the viral RNA, and then arouse a series of anti-viral reactions, including both humoral and cellular immune responses.46–49 It is necessary to know who recognizes whom first, ie, does it first begin with the SARS-CoV and SARS-CoV-2 to recognize host cells via the spike protein toward ACE2 or does it begin with the innate immune system to recognize SARS-CoV and SARS-CoV-2 via TLRs, RLRs, and NLRs?

The second prerequisite for cells to be infected by SARS-CoV and SARS-CoV-2 seems to be that the host cells have the cellular serine protease TMPRSS2 for spike protein priming, which is essential for SARS-CoV-2,50 SARS-CoV,51–54 and MERS-CoV,55,56 to enter into host cells. In fact, the alveolar type II cells in lung highly express TMPRSS2.52 Oppositely, it is not clear whether lymphocytes have TMPRSS2 or any similar protease, eg, endosomal cysteine proteases cathepsin B and L (CatB/L) because SARS-CoV can use these proteases to enter into host cells57 together with TMPRSS2.51,58,59
In a clinical study, mesenchymal stem cells (MSCs) were given to COVID-19 patients, since MSCs do not have ACE2 and TMPRSS2 but secrete anti-inflammatory factors, which is similar to the high doses of glucocorticoids, to prevent the cytokine storm. This result demonstrates the importance of ACE2-negative and TMPRSS2-negative cells. It really matters to ask whether the cells in the hypothalamic-pituitary-adrenal axis are ACE2- and TMPRSS2-positive or negative. This is so not only because SARS-CoV viral particles and genomic sequence were detected in the neurons of the brain but also because SARS-CoV initially triggers a stress response to stimulate the hypothalamic-pituitary-adrenal axis (middle-upper part in Figure 1).

In this way, it is fair to ask whether lymphocytes have TMPRSS2 since SARS-CoV viral particles and genomic sequence were widely detected (circulating lymphocytes, monocytes, and lymphoid tissues, as well as the epithelial cells of the respiratory tract, the mucosa of the intestine, the epithelium of the renal distal tubules, and macrophages in different organs).

Factors related to the entrance of SARS-CoV into host cells also include cathepsin L and a low endosomal pH as the fusion of viral particles and cytoplasmic membranes depends upon them. Naturally, cathepsin L or Ben·HCl is subjected to peptidase inhibitors but they are not the case for HNL63-CoV. Consequently, it is highly likely that SARS-CoV and SARS-CoV-2 do not infect lymphocytes directly and massively so one may wonder why lymphopenia occurs.

In summary, this section raises two questions. (a) Does it first begin with the SARS-CoV and SARS-CoV-2 to recognize host cells via the spike protein toward ACE2 or does it begin with the innate immune system to recognize SARS-CoV and SARS-CoV-2 via TLRs, RLRs, and NLRs? (b) Are the cells in the hypothalamic-pituitary-adrenal axis ACE2- and TMPRSS2-positive or negative?

3 | HOW DOES APOPTOSIS OCCUR IN LYMPHOCYTES?

No matter whether glucocorticoids or apoptosis bring about lymphopenia, the involvement of apoptosis is certain. Indeed, endogenous glucocorticoids can lead to apoptosis in T lymphocytes because lymphopenia is often found in patients without the administration of exogenous glucocorticoids. Apoptosis in alveolar epithelial cells and respiratory endothelial cells was found in humans and animals with acute lung injury and acute respiratory distress syndrome. Additionally, lymphocytes are rapidly dividing cells, whose death can minimize the inflammatory response to host. Besides, it showed that the low doses of corticosteroids can be useful in terms of apoptosis in lymphocytes.

In general, lymphocytes show an inversely correlated pattern with the cortisol diurnal rhythm. The function of T lymphocytes is influenced by glucocorticoids, which activate the expression of indoleamine-2,3-dioxygenase. This tryptophan-degrading enzyme regulates T-lymphocyte function via increased secretion of the anti-inflammatory cytokine IL-10 but the adrenal insufficiency would desensitize both α- and β-adrenergic receptors. And the transcription of the gene of the β2-adrenergic receptor is increased by glucocorticoids in human lung in vitro and nasal mucosa in vivo. Collectively, the functions of glucocorticoids are closely relevant to anti-inflammatory and inflammatory genes, which encode cytokines, chemokines, adhesion molecules, inflammatory enzymes, and receptors.

What is the direct link between apoptosis and corticosteroids? What mechanism is for glucocorticoids to initiate apoptosis in lymphocytes in COVID-19 patients? (right-hand lower part in Figure 1). Studies on the immune response to sepsis suggest a biphasic pattern, ie, a hyper-inflammatory response is associated with high levels of pro-inflammatory cytokines, but an immune-paralysis is associated with apoptosis of immune cells, in particular, with apoptosis of lymphocytes, which go through the death receptor (extrinsic) and the mitochondrial (intrinsic) pathways, converging to a common point, caspase 3 (left-hand lower part in Figure 1).

For COVID-19 patients, apoptosis in lymphocytes is attributed to the activation of the p53 signaling pathway in lymphocytes (right-hand lower part in Figure 1). Interestingly, the p53 pathway seems not to be involved in both extrinsic and intrinsic pathways, because the former needs death ligands, eg, FasL, TNF-α, APRIL, TRAIL, whereas the latter needs the intracellular stress, eg, reactive oxygen species, radiation, and chemotherapeutic agents. Accordingly, SARS-CoV and SARS-CoV-2 infection should serve as intracellular stress to trigger the intrinsic pathway to apoptosis under the condition that SARS-CoV or SARS-CoV-2 enters into lymphocytes (the black arrow on left-hand part in Figure 1). If this is the case, then the intrinsic pathway would be initiated to lead to apoptosis without the action of the extrinsic pathway although the cross-talk between two pathways exists in hepatocytes rather than in lymphocytes. Furthermore, the extrinsic pathway can trigger BCL-2-regulated apoptotic programs.

Activation of p53 can inhibit the replication of SARS-CoV in infected HEK293 and HCT116 cells but those cells are not lymphocytes and do not come from any immune system. This role of p53 with respect to SARS-CoV was found in the yeast-2-hybrid (Y2H) screen. Actually, p53 serves as an antiviral factor against positive-sense single-stranded RNA (ssRNA) hepatitis C virus (HCV) and poliovirus as well as negative-sense ssRNA influenza A virus and retrovirus HIV-1.

In summary, this section raises two questions. (1) Does apoptosis of lymphocytes occur inside or outside the circulation? (2) Which is the first between the SARS-CoV triggered
stress response through the hypothalamic-pituitary-adrenal axis to generate glucocorticoids and the immune response to SARS-CoV and SARS-CoV-2?

4 | CONCLUSION

In this paper, we attempt to address the contradiction that lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients because no other pneumonitis produces such a profound lymphopenia as seen in SARS and COVID-19 patients. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, we raise several questions, which need to be answered in order to better understand the whole course of COVID-19.

ACKNOWLEDGMENTS
This study was supported by the National Natural Science Foundation of China (31560315) and Key Project of Guangxi Scientific Research and Technology Development Plan (AB17195034).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTION
GW designed this review and wrote the first draft. SY composed the figures. Both finalized this manuscript.

ORCID
Shaomin Yan https://orcid.org/0000-0001-7642-3972
Guang Wu https://orcid.org/0000-0003-0775-5759

REFERENCES
1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.
4. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809.
5. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986-1994.
6. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216-228.
7. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24:3404-3410.
8. Cui W, Fan Y, Wu W, Zhang F, Wang YJ, Ni AP. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37:857-859.
9. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003;361:1701-1703.
10. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-1772.
11. Lu HY, Xu XY, Lei Y, et al. Clinical features of probable severe acute respiratory syndrome in Beijing. World J Gastroenterol. 2005;11:2971-2974.
12. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33.
13. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020;8:e24.
14. Fathi N, Rezaei N. Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int. 2020;44:1792-1797.
15. Girandot T, Rimmelé T, Venet F, Monneret G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis. 2017;22:295-305.
16. Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31:S253-S257.
17. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev. 1982;65:133-155.
18. Panesar NS, Lam CWK, Chan MHM, Wong CK, Sung JY. Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol. Eur J Clin Invest. 2004;34:382-384.
19. Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200:282-289.
20. Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34:743-748.
21. Lang Z, Zhang L, Zhang S, et al. Pathological study on severe acute respiratory syndrome. Chin Med J (Engl). 2003;116:976-980.
22. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202:415-424.
23. Panesar NS. Lymphopenia in SARS. Lancet. 2003;361:1985.
24. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449-1456.
25. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59:414-420.
26. Barnes PJ. Glucocorticoids: current and future directions. Br J Pharmacol. 2011;163:29-43.
27. Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and B lymphocytes to the bone marrow. Immunology. 1975;28:669-680.
28. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304-315.

29. Panesar NS. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med Hypotheses. 2008;71:298-301.

30. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9:761-770.

31. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.

32. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

33. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457-460.

34. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.

35. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879.

36. Hofmann H, Simmons G, Rennekamp AJ, et al. Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol. 2006;80:8639-8652.

37. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357:420-422.

38. Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A. 2005;102:7988-7993.

39. Hofmann H, Simmons G, Rennekamp AJ, et al. Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol. 2006;80:8639-8652.

40. Ge XY, Li J, Yang XL, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature. 2013;503:535-538.

41. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203:622-630.

42. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-637.

43. Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One. 2012;7:e35876.

44. Shieh WJ, Hsiao CH, Paddock CD, et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan. Hum Pathol. 2005;36:303-309.

45. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.

46. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59:118-128.

47. Fehr AR, Channappanavar R, Perlman S. Middle East respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med. 2017;68:387-399.

48. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immune pathology. Semin Immunopathol. 2016;38:471-482.

49. Nelemans T., Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. Viruses. 2019;11(10):961.

50. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.

51. Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85:4122-4134.

52. Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 contributes to virus spread and immune pathology in the airways of murine models after coronavirus infection. J Virol. 2019;93:e01815-18.

53. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyma S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537-6545.

54. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76-84.

55. Kleine-Weber H, Elzayat MT, Hoffmann M, Pöhlmann S. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep. 2018;8:16597.

56. Park JE, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A. 2016;113:12262-12267.

57. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005;102:11876-11881.

58. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658-12664.

59. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85:873-882.

60. Huang IC, Bosch BJ, Li F, et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem. 2006;281:3198-3203.

61. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2004;363:938-947.

62. Du L, Kao RY, Zhou Y, et al. Cleavage of spike protein of SARS-associated coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007;359:174-179.

63. Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938-947.
64. Wu XD, Shang B, Yang RF, et al. The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells. *Cell Res.* 2004;14:400-406.

65. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. *Cell Mol Life Sci.* 2006;63:60-72.

66. Tang PS, Mura M, Seth R, Liu M. Acute lung injury and cell death: how many ways can cells die? *Am J Physiol Lung Cell Mol Physiol.* 2008;294:L632-L641.

67. Hotchkiss RS, Coopersmith CM, Karl IE. Prevention of lymphocyte apoptosis - a potential treatment of sepsis? *Clin Infect Dis.* 2005;41:S465-S469.

68. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA.* 2002;288:862-871.

69. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. *N Engl J Med.* 2008;358:111-124.

70. Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. *Cytokine.* 1998;10:307-312.

71. Maneechotesuwan K, Supawita S, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. *J Allergy Clin Immunol.* 2008;121:43-50.

72. Goodman S, Sprung CL. International Sepsis Forum. The International Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock. *Crit Care.* 2002;6:381-383.

73. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. *Am J Physiol.* 1995;268:L41-L46.

74. Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. *Am J Respir Crit Care Med.* 1997;155:704-710.

75. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? *Ann Intern Med.* 2003;139:359-370.

76. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation – rationale for a new therapeutic strategy in sepsis. *Intensive Care Med.* 1996;22:S474-S481.

77. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. *Nat Med.* 1997;3:678-681.

78. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol.* 2006;6:813-822.

79. Weber SU, Schewe JC, Lehmann LE, et al. Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. *Crit Care.* 2008;12:R128.

80. Wheeler DS. Death to sepsis: targeting apoptosis pathways in sepsis. *Crit Care.* 2009;13:1010.

81. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. *Annu Rev Immunol.* 2003;21:71-105.

82. Ho T, Tan BX, Lane D. How the other half lives: what p53 does when it is not being a transcription factor. *Int J Mol Sci.* 2019;21:E13.

83. Ma-Lauer Y, Carabajo-Lozoya J, Hein MY, et al. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. *Proc Natl Acad Sci U S A.* 2016;113:E5192-E5201.

84. Pfefferle S, Schönpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS Pathog.* 2011;7:e1002331.

85. Mukerjee R, Claudio PP, Chang JR, Del Valle L, Sawaya BE. Transcriptional regulation of HIV-1 gene expression by p53. *Cell Cycle.* 2010;9:4569-4578.

86. Muñoz-Fontela C, Pazos M, Delgado I, et al. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. *J Immunol.* 2011;187:6428-6436.

87. Dharel N, Kato N, Muroyama R, et al. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. *Hepatology.* 2008;47:1136-1149.

88. Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. *J Virol.* 2006;80:8582-8592.

How to cite this article: Yan S, Wu G. Is lymphopenia different between SARS and COVID-19 patients?. *The FASEB Journal.* 2021;35:e21245. [https://doi.org/10.1096/fj.202002512](https://doi.org/10.1096/fj.202002512)